TG Therapeutics recently initiated an open-label Phase 2 trial of BRIUMVI (ublituximab-xiiy) in about 60 adults with ...

Dr. Daniel Ontaneda, a neurologist with Cleveland Clinic, said more than two dozen approved medications can help control MS ...

Earlier diagnostic options for MS are now possible, Zyn nicotine pouches get an FDA risk claim, and norovirus concerns rise.

Our latest CPD module explores five common but challenging neurology cases encountered in general practice, and discusses evidence-based approaches to assessment, investigation and management.

New diagnostic criteria for multiple sclerosis are helping doctors identify the disease sooner, allowing patients to begin treatment earlier.

True disruption demands both vision and courage, and these ten remarkable women are leading that charge in 2026.

A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B ...

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low ...

A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain.

Genomic surveillance—the process of monitoring and sequencing pathogens—is one of the most important tools for detecting ...

Pain remains one of the most prevalent and disabling non-motor consequences of neurological disease, yet it continues to be ...

This episode, titled 'NCCN Guidelines in Focus: Key Updates for Follicular Lymphoma and Their Impact on Formulary Decisions,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the following ...